Patel, M. R., Makker, V., Oaknin, A., Pignata, S., Jenniskens Backes, F., Gonzalez Martin, A., … Concin, N. (2022). Efficacy and safety of lucitanib plus nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).

Patel, Manish R., Vicky Makker, Ana Oaknin, Sandro Pignata, Floor Jenniskens Backes, Antonio Gonzalez Martin, Ramez Nassef Eskander, et al. “Efficacy and safety of lucitanib plus nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.

Patel MR, Makker V, Oaknin A, Pignata S, Jenniskens Backes F, Gonzalez Martin A, et al. Efficacy and safety of lucitanib plus nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO). In: JOURNAL OF CLINICAL ONCOLOGY. 2022.

Patel, Manish R., et al. “Efficacy and safety of lucitanib plus nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO).” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.

Patel MR, Makker V, Oaknin A, Pignata S, Jenniskens Backes F, Gonzalez Martin A, Nassef Eskander R, Pothuri B, Richardson DL, Alvarez Secord A, Van Nieuwenhuysen E, Liu JF, Musa F, Penson RT, Wride K, Lepley DM, Dusek R, Cameron T, Hamilton EP, Concin N. Efficacy and safety of lucitanib plus nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO). JOURNAL OF CLINICAL ONCOLOGY. 2022.